Opus Genetics Gets FDA Clearance to Begin Gene Therapy Trial for Inherited Childhood Blindness

Key Points

• The FDA cleared Opus Genetics’ application to begin clinical testing of OPGx-RDH12 for a rare inherited retinal disease.
• Opus plans to initiate a Phase 1/2 trial in the fourth quarter of 2026.
• The experimental therapy is designed to deliver a working copy of the RDH12 gene to light-sensing cells in the retina.
• Patient organizations in the Global RDH12 Alliance committed up to $1.6 million to support development.
• The clearance permits clinical testing—it is not approval to market the treatment.

Opus Genetics (NASDAQ: IRD) has received FDA clearance to advance OPGx-RDH12, its investigational gene therapy for RDH12-associated Leber congenital amaurosis, or RDH12-LCA.

The condition causes progressive vision loss beginning in early childhood. The announcement moves the program toward human testing, making it Opus’s third gene therapy program to reach clinical development.

Phase 1/2 Trial Is Planned to Begin This Quarter

Opus plans to initiate a Phase 1/2 study before the end of 2026. The announcement does not provide enrollment targets, a detailed trial design or an expected results date.

The FDA’s clearance of the Investigational New Drug application allows clinical testing to proceed. It does not establish that the therapy is safe or effective.

Gene Therapy Aims to Address the Underlying Genetic Defect

RDH12-LCA results from mutations in the RDH12 gene that disrupt protein function in the retina. According to the company, the disease affects an estimated 30,900 people worldwide.

OPGx-RDH12 uses an adeno-associated virus, or AAV, delivery system to carry a functional copy of the gene to photoreceptors—the retina’s light-sensing cells.

Cell and mouse studies showed restored RDH12 activity and functional improvements. Those findings support human evaluation, but they do not demonstrate that the treatment can preserve or improve patients’ vision.

Patient Organizations Contribute Funding and Development Input

The program is supported by the Global RDH12 Alliance, which includes the U.S.-based RDH12 Fund for Sight and the U.K.-based Eyes on the Future.

Under a collaboration established in July 2025, the alliance committed up to $1.6 million toward eligible development costs, subject to specified obligations and milestones.

The organizations are also contributing to clinical and regulatory planning, bringing patient and family perspectives into the development process.

Investor Takeaway: A Clinical Milestone, With Human Results Still Ahead

For IRD investors, the clearance advances another program into clinical development and highlights the role of patient-backed funding.

The next milestones are trial initiation, enrollment and human safety and activity results. The announcement contains no patient treatment results or evidence of a confirmed vision benefit.